In conclusion, we showed here that bufalin could reverse HGF-induced resistance to EGFR-TKIs by inhibiting Met/PI3K/Akt pathway and activating death signaling in EGFR mutant lung cancer cells. The gene discussed is EGFR; the disease is lung carcinoma.